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Abstract
Background Stress-induced Tako-tsubo cardiomyopathy
(TTC) is an acute cardiac syndrome, mimics ST elevation
myocardial infarction (STEMI), largely confined to post-
menopausal women, frequently precipitated by a stressful
event. The pathogenesis of TTC is still unknown. Some
authors hypothesized a possible connection between TTC
and anxiety disease, but no previous study analyzed the
relationship between anxiety trait and TTC. This study
sought to assess the potential role of anxiety trait in the
development and clinical course of TTC.
Methods We included in the present prospective case–
control study 50 consecutive patients admitted to our
Hospital with a diagnosis of TTC according to the Mayo
Clinic criteria. Fifty control patients with anterior STEMI
matched for clinical characteristics such as age, gender,
and hypertension were selected. During the hospitalization,
all patients were asked to complete the Spielberger Trait
Anxiety Inventory (STAI) scale for measuring self-repor-
ted trait anxiety (Trait-A). Outcome measures at follow-up
were death, TTC recurrence, and rehospitalization.
Results The mean value of STAI scale was 46 ± 12 in
TTC patients and 45 ± 14 in STEMI patients (p = 0.815).
High-anxiety trait (STAI scale value C 40) was docu-
mented in 30 (60%) TTC patients and in 26 (52%) STEMI
patients (p = 0.387). At multivariate analysis, predictors of
TTC were lower peak creatine kinase value (HR 0.999;
95% CI 0.998–0.999; p = 0.018) and an antecedent
stressful trigger event (HR 45.487; 95% CI 6.471–319.759;
p = 0.001), but anxiety trait was not. There were no dif-
ferences in outcome measures between TTC patients with
or without high-anxiety trait.
Conclusion In TTC patients, high-anxiety trait is a
common finding but it is not significantly more frequent
than in patients with STEMI. Moreover, a high-anxiety
trait seems to be neither associated with a worse clinical
outcome nor a predictor of TTC. Our study do not support
the routine evaluation of anxiety trait in patients with TTC.
Keywords Stress-induced Tako-tsubo cardiomyopathy 
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Introduction
Stress-induced cardiomyopathy or Tako-tsubo cardiomyop-
athy (TTC) or transient left ventricular ballooning syndrome is
a clinical condition largely confined to postmenopausal
women, frequently precipitated by a stressful event. TTC
mimics a ST segment elevation acute myocardial infarction
(STEMI), and it is associated with a reversible regional dys-
function of the left ventricle without angiographic evidence
of obstructive atherosclerosis of epicardial coronary arteries
[1–6].
The pathogenesis of TTC is still unknown but the main
hypothesis indicates the central role of activation of sym-
pathetic nervous system (SNS) and catecholamine surge
induced by mental or physical stress [2, 7].
Previous studies highlighted anxiety disorders are
thought to involve a dysregulation of neurotransmitter
systems with particular regard to noradrenaline, serotonin,
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c-aminobutyric acid, dopamine, and cholecystokinin [8–10].
In light of these suggestions, some authors hypothesized
possible connection between TTC and anxiety disorders
[11]. No previous study analyzed specifically the relation-
ship between anxiety trait and TTC.
We sought to assess the potential role of anxiety trait in
the development and the clinical course of stress cardio-
myopathy comparing TTC patients with patients admitted
for STEMI.
Materials and methods
The present study was a prospective case–control study
conducted from April 2005 to January 2009. Eligible case
patients included consecutives subjects admitted to our
Hospital with a diagnosis of TTC, who met all the four
diagnostic criteria: (1) transient hypokinesis, akinesis or
diskinesis of the left ventricular mid segments with or
without apical involvement; the regional wall-motion
abnormalities extend beyond a single epicardial vascular
distribution; a stressful trigger is often, but not always
present; (2) new ECG abnormalities (either ST-segment or
T-wave inversion) or modest elevation in cardiac troponin;
(3) absence of obstructive CAD or angiographic evidence
of plaque rupture; (4) absence of pheochromocytoma,
myocarditis, hypertrophic cardiomyopathy [2]. The control
group consisted of patients admitted in the same period for
anterior STEMI [12]. Subsequent to enrollment of case,
eligible control patients with the same gender, age, and
history of hypertension were matched individually to each
case patient [13].
After coronary angiography, and coronary revasculari-
zation if indicated, all TTC and STEMI patients were
admitted to the coronary care unit and monitored for ECG
and cardiac enzyme changes. ECG was performed at
admission and at 6 h, then every 24 h until hospital dis-
charge. Two-dimensional, Doppler and color echocardio-
graphic evaluations were performed at admission and every
2 days until hospital discharge.
Patients were asked to complete the Spielberger State-
Trait Anxiety Inventory (STAI) trait anxiety scale to
measure anxiety symptoms before hospital discharge when
they were medically stable. The STAI is a scale for mea-
suring self-reported trait anxiety (Trait-A). Differently
from State anxiety (State-A) that is the emotional status
evoked by a condition, which is transitory, lasting for
minutes, hours, or days, Trait-A refers to relatively
enduring individual differences in anxiety proneness (i.e.,
diathesis of emotional vulnerability, which accounts for
differences between people in the tendency to perceive
stressful situations as dangerous or threatening). Of note,
Trait-A scores remain essentially unchanged before and
after external stress. A cut-off value of 40 for Trait-A score
has been used to dichotomize patients into low- and high-
anxiety groups [14, 15].
Informed consent was obtained from all the cases and
the controls. The study was approved by the local ethics
committee.
After hospital discharge, patients were asked to return to
our outpatient clinic for follow-up evaluation at 6 months
and then annually thereafter. Patients who failed to show
up at scheduled visits were contacted by telephone
interview.
Primary end-point was the percentage of patients with
high-anxiety trait (STAI scale value C 40).
Major events were defined as death, recurrence of
STEMI or TTC, and rehospitalization for any cause.
Antecedent stressful trigger event was defined as an
occurrence that produced short-term physiological changes
that may lead directly to the onset of acute cardiovascular
disease [16].
The study was designed on the following basis: the
primary end-point rate in TTC patients will be higher than
in the control group. We assumed the primary end-point
would occur in 52% TTC patients and in 26% STEMI
patients [14]. The planned enrollment of 50 patients for
each group provides 90% power of detecting the primary
end-point.
Continuous data are expressed as mean ± standard
deviation, and categorical data as proportions (%). Baseline
data were compared by means of the Chi-square test for
categorical variables and unpaired t test for continuous
variables. Forward stepwise Cox multiple logistic regres-
sion analysis was used to identify independent predictors of
TTC in the overall population of patients with suspected
anterior STEMI. Variables tested in the model were age,
gender, systolic blood pressure, diabetes mellitus, hyper-
cholesterolemia, smoke, comorbidity, stressful trigger
event, clinical presentation, ejection fraction at admission,
systolic blood pressure, Troponin I at admission, peak
creatine kinase-mb, total creatine kinase peak, high-anxiety
trait. Differences in major events were assessed by exact
log-rank test. Hazard ratios (HR) and 95% confidence
intervals (CI) were calculated. Statistical significance was
defined as p value \ 0.05. Statistical analysis was per-
formed with SPSS 16 (SPSS, Inc., Chicago, IL, USA).
Results
Fifty patients with TTC and 50 patients with STEMI were
included in the study. The baseline characteristics of the
two matched groups are summarized in Table 1. Patients
with TTC showed lower incidence of diabetes mellitus,
lower value of cardiac enzymes peak, higher presence of an
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Table 1 Baseline characteristics and clinical findings of patients with Stress cardiomyopathy, of patients with ST elevation myocardial
infarction and of Stress cardiomyopathy patients divided in high- and low-anxiety trait groups (STAI Trait-A C40)
Stress
cardiomyopathy
(n = 50)
ST elevation
myocardial
infarction (n = 50)
p value Stress cardiomyopathy p value
High-anxiety trait
group (n = 30)
Low- anxiety trait
group (n = 16)
Age (years)* 73 ± 9 73 ± 9 1 71 ± 9 76 ± 8 0.091
Female* 47 (94%) 47 (94%) 1 29 (97%) 15 (94%) 0.644
Hypertension* 27 (54%) 27 (54%) 1 17 (57%) 7 (44%) 0.404
Previous myocardial infarction
(or Stress cardiomyopathy)
3 (6%) 3 (6%) 1 3 (10%) 0 (0%) 0.191
Diabetes mellitus 2 (4%) 9 (18%) 0.025 1 (3%) 1 (6%) 0.644
Hypercholesterolemia 14 (28%) 19 (38%) 0.288 11 (37%) 3 (19%) 0.202
Smoke 14 (28%) 7 (14%) 0.086 8 (27%) 5 (31%) 0.742
Familar history of coronary artery disease 6 (12%) 3 (6%) 0.295 6 (20%) 0 (0%) 0.055
Comorbidity 35 (71%) 30 (60%) 0.231 22 (73%) 10 (63%) 0.447
Previous coronary artery bypass graft 0 (0%) 1 (2%) 0.315 0 (0%) 0 (0%)
Previous percutaneous coronary intervention 0 (0%) 4 (8%) 0.039 0 (0%) 0 (0%)
Clinical presentation
Chest pain 35 (70%) 49 (98%) 0.004 23 (77%) 10 (62%) 0.883
Dyspnea 4 (8%) 1 (2%) 2 (7%) 2 (13%)
Syncope 2 (4%) 0 (0%) 1 (3%) 1 (6%)
Other symptoms 9 (18%) 0 (0%) 4 (13%) 3 (19%)
Stressful trigger event 40 (80%) 4 (8%) 0.000 23 (77%) 14 (86%) 0.378
Ejection fraction at admission 37 ± 9 36 ± 8 0.415 38 ± 9 39 ± 9 0.841
Ejection fraction at discharge 48 ± 11 43 ± 9 0.048 48 ± 10 51 ± 15 0.344
Systolic blood pressure (mmHg) 122 ± 23 122 ± 24 0.988 124 ± 24 123 ± 21 0.873
Diastolic blood pressure (mmHg) 72 ± 16 71 ± 14 0.855 71 ± 16 75 ± 16 0.506
Heart rate (bpm) 77 ± 15 74 ± 14 0.426 75 ± 16 79 ± 15 0.390
Troponin I at admission (ng/mL) 6 ± 10 52 ± 90 0.001 6 ± 12 5 ± 6 0.710
Peak troponin I (ng/mL) 8 ± 11 184 ± 385 0.003 9 ± 13 7 ± 6 0.635
Peak creatine kinase-mb (UI/L) 25 ± 43 927 ± 1439 0.000 27 ± 50 12 ± 10 0.305
Peak creatine kinase (UI/L) 358 ± 451 1614 ± 1667 0.000 291 ± 302 348 ± 348 0.596
Intra-aortic balloon pump 1 (2%) 5 (11%) 0.068 1 (3%) 0 (0%) 0.460
Shock 0 (0%) 2 (4%) 0.153 4 (14%) 2 (13%) 0.966
Dual antiplatelet therapy at discharge 6 (13%) 46 (94%) 0.000 22 (76%) 13 (87%) 0.400
Beta-blockers at discharge 37 (77%) 32 (65%) 0.320 18 (62%) 5 (33%) 0.070
ACEI at discharge 25 (52%) 38 (78%) 0.009 1 (3%) 2 (13%) 0.218
ARBS at discharge 3 (6%) 1 (2%) 0.307 15 (52%) 5 (33%) 0.246
Statin at discharge 21 (44%) 43 (88%) 0.000 3 (10%) 1 (7%) 0.687
Calcium channel blockers at discharge 5 (10%) 1 (2%) 0.092 1 (3%) 0 (0%) 0.460
Level of instruction
Primary school 18 (55%) 27 (66%) 0.090 15 (63%) 3 (33%) 0.292
Secondary school 7 (21%) 6 (14%) 4 (17%) 3 (33%)
High school 5 (15%) 8 (19%) 3 (13%) 2 (23%)
Degree 3 (9%) 0 (0%) 2 (7%) 1 (11%)
STAI Trait-A scale value 46 ± 12 45 ± 14 0.815 52 ± 9 33 ± 5 –
High-anxiety trait (STAI scale value C40) 30 (60%) 26 (52%) 0.387 – – –
ACEI inhibitors of Angiotensin-converting enzyme, ARBs angiotensin receptor blockers
* According to case–control matching
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antecedent stressful trigger event, and higher degree of left
ventricular systolic function recovery at discharge than
patients with STEMI. The main clinical presentation in
TTC was chest pain (70%), but also dyspnea (8%), syncope
(4%), malaise or other symptoms (18%) were found, while
in STEMI chest pain was the clinical presentation in 98%
of patients. Four patients with TTC and two with STEMI
were unable to perform STAI trait-A test for cognitive
disease or for denial to complete the test. The mean value
of STAI scale was 46 ± 12 in TTC patients and 45 ± 14
in STEMI patients (p = 0.815). High-anxiety trait (STAI
Trait-A scale value C 40) was documented in 30 (60%)
TTC patients and in 26 (52%) STEMI patients (p = 0.387).
At multivariate analysis of the 100 patients, predictors of
TTC were lower peak creatine kinase value (HR 0.999;
95% CI 0.998–0.999; p = 0.018) and an antecedent
stressful trigger event (HR 45.487; 95% CI 6.471–319.759;
p = 0.001), but anxiety trait was not. The follow-up rate
was 100%. Follow-up data showed a lower rate of major
events in TTC patients (30%) than in STEMI patients
(42%; p = 0.034) and a trend toward a lower rate of car-
diac and all causes rehospitalizations in TTC patients
(p = 0.087 and p = 0.094, respectively; Table 2). The
only patient with recurrence of TTC had a low-anxiety trait
(value 33) while both patients with recurrence of STEMI
had a high-anxiety trait (value 63 and 66).
TTC patients were divided into high- (n = 30) and low-
(n = 16) anxiety trait groups. There were no differences in
baseline characteristics and in outcome measures between
the two groups (Tables 1, 2). Patients with TTC were also
analyzed according to the presence (n = 40) or the absence
(n = 10) of antecedent stressful trigger event. Antecedent
stressful trigger events that occurred in TTC patients are
specified in Table 3. Patients with a stressful trigger event
showed a similar high-anxiety trait rate as compared to
those without (58% vs. 70%; p = 0.659), and a lower
instruction level rather than patients without stressful
trigger event (p = 0.010). Moreover, there was no differ-
ence in outcome measures between TTC patients with and
without antecedent stressful event (Table 4).
Table 2 Clinical outcomes at follow-up
Stress
cardiomyopathy
(n = 50)
ST elevation myocardial
infarction (n = 50)
p value
(log-rank test)
Stress cardiomyopathy p value
High-anxiety trait
group (n = 30)
Low-anxiety trait
group (n = 16)
Follow-up time (months) 11 ± 11 25 ± 19 0.001 12 ± 10 11 ± 12 0.748
Death 2 (4%) 2 (4%) 0.443 0 (0%) 0 (0%) 1
Re MI o TTC 1 (2%) 2 (4%) 0.455 0 (0%) 1 (6%) 0.166
Chest pain 8 (16%) 15 (30%) 0.083 7 (23%) 1 (6%) 0.145
NYHA classification [2 4 (8%) 6 (12%) 0.526 1 (3%) 3 (19%) 0.207
Rehospitalization 13 (26%) 20 (40%) 0.094 7 (23%) 5 (31%) 0.560
Cardiac rehospitalization 10 (20%) 13 (26%) 0.087 6 (20%) 4 (25%) 0.695
Major event* 15 (30%) 21 (42%) 0.034 7 (23%) 5 (31%) 0.560
MI myocardial infarction, TTC Tako-tsubo Cardiomyopathy, NYHA New York Heart Association
* Major event is defined as: death, recurrence of MI or TTC, and rehospitalization for any cause
Table 3 Antecedent stressful trigger event in Stress cardiomyopathy
patients
Patients (n = 50)
Stress present 40 (80%)
Psychological stress 23 (58%)
Violent argument 6
Death of relative, friend or pet 3
Fear/sorrow 8
Husband hospitalization
Grandson car incidence
Daughter’s splitting-up
Anniversary of the death of daughter
Departure of sons for holidays
Diagnosis of disease of a relative
Unknown 6
Physical Stress 17 (43%)
Physical exercise 2
Medical or surgical procedures 5
Anesthesia induction
Dental extraction
Corneal transplantation
Cholecystectomy
Onset of diseases 5
Epilepsy
Atrial fibrillation
Chronic obstructive pulmonary disease
Flu
Other 5
Accidental fall
Bone fracture
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Table 4 Baseline
characteristics and clinical
findings of patients with Stress
cardiomyopathy with and
without stressful event in the
clinical history
ACEI inhibitors of Angiotensin-
converting enzyme, ARBs
angiotensin receptor blockers,
NYHA New York Heart
Association
* Major event is defined as:
death, recurrence of TTC or
rehospitalization for any cause
Stress cardiomyopathy (n = 50) p value
Patients with
stressful trigger
event (n = 40)
Patients without
stressful trigger
event (n = 10)
Age (years) 73 ± 9 72 ± 10 0.662
Female 38 (95%) 9 (90%) 0.552
Hypertension 21 (53%) 6 (60%) 0.670
Diabetes mellitus 2 (5%) 0 (0%) 0.470
Hypercholesterolemia 11 (27%) 3 (30%) 0.875
Smoke 10 (25%) 4 (40%) 0.345
Familiar history of coronary artery disease 5 (13%) 1 (10%) 0.828
Comorbidity 27 (68%) 9 (90%) 0.156
Previous stress cardiomyopathy 3 (8%) 0 (0%) 0.372
Clinical presentation
Chest pain 30 (75%) 5 (50%) 0.181
Dyspnea 2 (5%) 2 (20%)
Syncope 2 (5%) 0 (0%)
Other symptoms 6 (15%) 3 (30%)
Intra-aortic balloon pump 1 (3%) 0 (0%) 0.614
Dual antiplatelet therapy at discharge 5 (13%) 1 (10%) 0.788
Beta-blockers at discharge 30 (79%) 7 (70%) 0.549
ACE Inhibitors at discharge 18 (47%) 7 (70%) 0.202
ARBS at discharge 3 (8%) 0 (0%) 0.359
Statin at discharge 18 (47%) 3 (30%) 0.325
Calcium channel blockers at discharge 5 (13%) 0 (0%) 0.226
Level of instruction
Primary school 17 (68%) 1 (13%) 0.010
Secondary school 3 (12%) 4 (48%)
High school 4 (16%) 1 (13%)
Degree 1 (4%) 2 (26%)
Ejection fraction at admission 37 ± 9 40 ± 10 0.430
Ejection fraction at discharge 48 ± 12 52 ± 10 0.463
Systolic blood pressure (mmHg) 125 ± 24 115 ± 15 0.240
Diastolic blood pressure (mmHg) 72 ± 16 70 ± 16 0.675
Heart rate (bpm) 78 ± 14 70 ± 16 0.140
Troponin I at admission (ng/mL) 5 ± 7 9 ± 19 0.378
Troponin I peak (ng/mL) 7 ± 8 11 ± 18 0.368
Creatin kinase-mb (UI/L) 22 ± 44 36 ± 40 0.415
Creatin kinase (UI/L) 272 ± 255 667 ± 794 0.013
STAI Trait-A scale value 46 ± 13 46 ± 8 0.937
High-anxiety trait (STAI scale value C40) 23 (58%) 7 (70%) 0.659
Follow-up clinical outcomes
Follow-up time (months) 13 ± 12 7 ± 4 0.116
Death 1 (3%) 1 (10%) 0.279
Recurrence of TTC 1 (3%) 0 (0%) 0.627
Chest pain 6 (15%) 2 (20%) 0.620
NYHA classification [2 2 (5%) 2 (20%) 0.072
Rehospitalization 11 (28%) 2 (20%) 0.716
Cardiac rehospitalization 8 (20%) 2 (20%) 0.909
Major event 12 (30%) 3 (30%) 1
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Discussion
The main findings emerged from this study were the fol-
lowing: (1) in TTC patients a high-anxiety trait is a com-
mon finding; (2) high-anxiety trait prevalence in TTC
patients was not significantly higher as compared with
STEMI patients and anxiety trait was not a predictor of
TTC in patients presenting with chest pain or dyspnea with
suspected anterior STEMI; (3) a high-anxiety trait seems
not to be associated with the worse clinical outcome in
TTC; (4) the role of antecedent stressful trigger event still
remain an important clinical feature of TTC, and it is
independent from patient’s anxiety trait.
The physiopathological mechanism of TTC is still
unknown. Previous studies reported very high levels of
catecholamine at TTC presentation, which remained ele-
vate until 7–9 days [15]. The most likely mechanism
involves the central role of SNS and catecholamine surge
induced by mental or physical stress, that in patients with
individual susceptibility may lead to microvascular spasm,
or left ventricular outflow tract obstruction, or direct
myocyte injury, or metabolic disorders such as abnormal-
ities in free fatty acid metabolism and glucose uptake
leading to myocardial stunning [2, 16, 17].
Anxiety is a negative emotion characterized by per-
ceived inability to predict, control, or gain the preferred
result when confronted with a threat coming from internal
or external sources and can be real or imagined. Anxiety
exists on a continuum from normal to pathological condi-
tion [18].
The precise mechanisms underlying the pathogenesis of
anxiety remain unclear. Previous studies demonstrated
pathological alteration in cardiac autonomic tone involving
either increased sympathetic stimulation, or impaired vagal
control in anxiety patients [19, 20]. The key role of sero-
tonin system dysregulation in anxiety development has
been demonstrated to involve the serotonin-1A (5-HT1A)
subtype receptor [20]. The role of catecholamines, in par-
ticular of noradrenaline, is less clear. Substantial evidence
supports the hypothesis of a disturbed noradrenergic neu-
rotransmission (adrenergic receptors a1, a2, b1, b2) con-
tributing to anxiety symptoms [21–24]. Previous studies
highlighted increase noradrenaline release, receptors dys-
regulation or dysregulation of the brain noradrenergic
system in patients with anxiety disease [8, 9]. Moreover,
catecholamines receptors down-regulation may occur in
such condition, due to the chronic overactivity of central
norepinephrine in anxiety patients [25].
The diagnosis of a psychiatric disease, as anxiety or
depression, increase the risk of cardiac and all causes
mortality in patients affected by heart diseases [14, 26],
thus anxiety trait may be considered a cardiovascular risk
factor [27]. A possible relationship between TTC and
anxiety trait has been hypothesized but never assessed in
prospective clinical studies [11].
Our study failed to show a correlation between anxiety
trait and TTC. TTC clinical course seems not to be influ-
enced by anxiety, since clinical outcomes were similar
between patients with and without high-anxiety trait, and
STAI Trait-A test result was not a predictor of any clinical
event at follow-up.
In light of these results, it seems that typical catechol-
amines alteration of anxiety disease, through increased
release or by receptor dysregulation, is not a risk factor or a
predictive clinical condition of TTC development. Con-
versely, a single acute stressful trigger event, associated
with sudden and rapid surge of catecholamines levels, can
induce stress cardiomyopathy. Thus, we hypothesized that
TTC patients might be able to respond in an abnormal way
to an abrupt rise of catecholamines levels rather than to
their absolute basal levels.
A history of antecedent stressful event, emotional or
physical, was described in the majority of TTC patients
[7]. Acute stress triggers myocardial ischemia, promotes
arrhythmogenesis, stimulates platelet aggregation, and
increases blood viscosity through hemoconcentration
[28, 29]. SNS stimulation produced from acute stress leads
to a variety of effects, ranging from heart rate and blood
pressure rise to direct effects on coronary vascular endo-
thelium [30].
Protection against triggers, through stress reduction
training or by anticipation of possible stress events, may
provide a further rationale for daily therapy to limit anger
and anxiety. Although selective serotonin reuptake inhibi-
tors has been previously proposed [30], our study does not
support the use of anxiety therapy to avoid TTC onset or
recurrence.
Study limitations
Our results must be evaluated in light of some study lim-
itation. First, the sample size may constitute an issue.
However, TTC is considered a rare syndrome, and 50
individuals are a relevant study population in relation to the
prevalence of the analyzed syndrome and may provide
clinically useful information. To our knowledge, this is the
very first report of anxiety trait in patients with TTC. No
data are available regarding anxiety status influence on the
acute phase course of tako-tsubo cardiomyopathy. There
are also few data about anxiety trait in patients with
STEMI, i.e., a much more prevalent clinical condition.
Second, our analysis might have suffered from the limita-
tions of case–control study. However, it is well known that
this kind of analysis is ideal for rare diseases such as stress
cardiomyopathy. We cannot exclude the limited power of a
single evaluation of the Spielberger scale in exploring the
528 Clin Res Cardiol (2011) 100:523–529
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complexity of anxiety disorder. Third, it is unknown if a
longer follow-up would provide further information about
TTC natural history. Finally, all the enrolled patients
belong to the same country and it is unknown if people
living in different countries may potentially respond and
cope with stressful situations differently.
In conclusion, in TTC patients high-anxiety trait is a
common finding but it is not significantly more frequent
than in patients with STEMI. Moreover, a high-anxiety
trait seems to be neither associated with a worse clinical
outcome or a predictor of TTC. Our study do not support
the routine evaluation of anxiety trait in patients with TTC.
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